Business Wire

MBZIRC

28.9.2021 13:46:05 CEST | Business Wire | Press release

Share
Abu Dhabi’s ASPIRE Launches Over US$3 Million MBZIRC Maritime Grand Challenge

The Mohamed Bin Zayed International Robotics Challenge (MBZIRC) will be held in the UAE capital, Abu Dhabi, in June 2023, where tech innovators will participate to seek marine safety and security solutions to take home more than US$3 million in prize money.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005641/en/

Organised by ASPIRE, the dedicated technology programme management pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology research body in Abu Dhabi, UAE, the MBZIRC is held every two years. The upcoming edition, called MBZIRC Maritime Grand Challenge, focuses on real-time solutions to maritime safety and security challenges and seeks to claim its place among the largest and most prestigious AI and robotics competitions in the world.

The Challenge is open to international universities, research institutions, companies and individual innovators from all over the world. It will involve a heterogeneous collaboration among unmanned aerial vehicles and unmanned surface vehicles, to perform complex navigation and manipulation tasks in a GNSS-denied environment. Call for registrations is now open.

Commenting on the announcement, H.E. Faisal Al Bannai , Secretary General of ATRC, said: “We are proud that MBZIRC is going global by inviting the best talent from all over the world to participate. We have set a tough real-world challenge that will push the participants to the limits of their capabilities. The event is a great opportunity to demonstrate the pioneering scientific research work that is taking place in Abu Dhabi and the UAE.”

The challenge will show how both entities focus on niche areas of technology, while attracting global innovators to stimulate ideas, encourage collaboration, and push boundaries in advanced technologies to find systems solutions to global challenges.

“For countries with long coastlines, ensuring maritime safety requires significant investment in sophisticated equipment and highly trained personnel. Using advanced robotic systems can not only help reduce costs, but also handle some of the often- dangerous tasks performed by humans. The motivation for holding the MBZIRC Maritime Grand Challenge is to take the technology out of the laboratory and test it in a real-world environment to see what is possible,” said Dr Arthur Morrish, Chief Executive of ASPIRE.

Dr Morrish underscored the two-fold purpose behind the competition: one is to focus on the important problems in autonomy of robotics while engaging the world community in a hard robotics challenge. The other is to find a solution to a real-world challenge facing the world.

The challenge is for a swarm of UAVs to identify a target vessel from several similar vessels in open waters in a GNSS-denied environment, and to offload specific items from the target onto an USV in the shortest possible time using autonomous technologies. This is a new kind of kind of exercise in autonomous robotics. “A nice thing about this challenge is that you tell people what you want, but you don’t specify an approach to do it,” Dr Morrish added.

He said that this kind of a smart system will have practical application in other areas as well, especially as it can perform complex tasks of autonomous intervention in a GNSS-denied environment.

For more information, visit www.mbzirc.com

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye